[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"small-intestinal-bacterial-overgrowth-syndrome-sibo\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:small-intestinal-bacterial-overgrowth-syndrome-sibo":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,77,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100625751","phase-4-effect-of-multispecies-probiotic-supplementation-on-the-efficacy-of-rifaximin--therapy-in-patients-with-small-intestinal-bacterial-overgrowth-sibo-a-randomized-placebo-controlled-trial-100625751",false,"NCT07426705","Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial","Effect of Enterococcus Faecium and Bacillus Subtilis-Containing Multispecies Probiotic Supplementation on the Therapeutic Efficacy of Rifaximin α in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Prospective, Randomized, Placebo-controlled Trial","SIBO-Probiotic","Inclusion Criteria:\n\n* Age ≥18 years.\n* Meets Rome IV criteria for irritable bowel syndrome.\n* Written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Lack of cooperation with investigators.\n* Age \\>75 years.\n* Need for modification of gastrointestinal treatment during the study.\n* Use of antibiotics within 4 weeks before screening.\n* Use of probiotics within 7 days before screening.\n* Endoscopic examination within 6 weeks before screening or during the study without investigator approval.\n* History of abdominal surgery.\n* Crohn's disease, ulcerative colitis, microscopic colitis, celiac disease, cystic fibrosis, chronic pancreatitis, liver cirrhosis, or end-stage renal disease.\n* Low FODMAP diet within 4 weeks before screening.\n* Pregnancy or breastfeeding.\n* Lactulose intolerance.","ALL","18 Years","75 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Small intestinal bacterial overgrowth (SIBO) is a common condition associated with gastrointestinal symptoms such as bloating, abdominal pain, diarrhea, and constipation, particularly in patients with irritable bowel syndrome. Antibiotic therapy with rifaximin is commonly used, but relapse rates remain high.\n\nThis randomized, placebo-controlled clinical trial aims to evaluate whether supplementation with a multispecies probiotic containing Enterococcus faecium and Bacillus subtilis improves the effectiveness of rifaximin therapy in adult patients with SIBO.\n\nParticipants will be randomly assigned to receive either rifaximin plus the probiotic or rifaximin plus placebo. Clinical assessments will include hydrogen breath testing and evaluation of gastrointestinal symptoms using standardized questionnaires at baseline and during follow-up visits.\n\nThe study is being conducted at a single academic medical center in Poland and is sponsored by Państwowy Instytut Medyczny MSWiA. The probiotic and rifaximin are provided by Urgo.\n\nThe results of this study may help determine whether probiotic supplementation can improve treatment outcomes and reduce recurrence of SIBO.",[28,29],"Small Intestinal Bacterial Overgrowth Syndrome (SIBO)","IBS",[31,29,32],"SIBO","probiotic","NOT_YET_RECRUITING","2026-02-16",{"date":36,"type":37},"2026-02-23","ACTUAL",{"date":39,"type":22},"2026-02-15",{"date":41,"type":22},"2027-07-15",{"name":43,"class":44},"Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji","OTHER_GOV",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100604135","combined-lactulose-h2-breath-test-with-abdominal-imaging-100604135","NCT07145580","Combined Lactulose H2-breath Test With Abdominal Imaging","Clinical Application of a Combined Lactulose H2-breath Test With Abdominal Imaging to Assess the Digestive Function: a Retrospective Cohort Study","Inclusion Criteria:\n\n* Patients referred for breath testing to assess the causes of digestive symptoms or maldigestion 2020-2024\n* Patients signed general consent to allow use of clinical data obtained during clinical assessment and breath testing to be used in research project.\n\nExclusion Criteria:\n\n\\-",{"count":53,"type":22},500,"OBSERVATIONAL","Hydrogen (H₂) breath tests serve several purposes. (i) detect malabsorption of carbohydrates such as lactose and fructose, (ii) measurement of oro-caecal transit time (iii) associate hydrogen production with the onset of abdominal symptoms like bloating, flatulence, pain, and diarrhea (which indicates carbohydrate intolerance), and (iv) diagnose small intestinal bacterial overgrowth (SIBO).\n\nIt is important to distinguish between carbohydrate intolerance and SIBO because their treatments differ significantly. Carbohydrate intolerance is typically managed through dietary restrictions, while SIBO requires antibiotic therapy. However, recent guidelines have questioned the accuracy of hydrogen breath tests in diagnosing SIBO due to variability in OCTT measurements. This limitation can be addressed by combining H₂ breath tests with imaging techniques such as scintigraphy, which independently confirm OCTT. When this combined approach is used, SIBO is diagnosed if the rise in breath H₂ occurs before the contrast agent appears in the large bowel. Despite its benefits, this combined method faces organizational and financial challenges that limit its routine clinical use.\n\nThis retrospective cohort study aims to assess the clinical performance of a cheap and simple test that combines a 20g lactulose H₂ breath test with simple radiographic abdominal imaging to assess OCTT, SIBO, and carbohydrate tolerance. The novel innovation in this method is to confirm oro-caecal transit by taking an X-ray of the abdomen when H₂ production increases during the examination. If the contrast agent is not visible in the cecum when H₂ rises, this indicates the presence of SIBO. Conversely, if the contrast agent is present in the cecum at that time, it confirms normal OCTT, and any abdominal symptoms occurring after this point support a diagnosis of carbohydrate intolerance.\n\nIf the method is proven to be valid, then this simple test will greatly facilitate the accurate diagnosis of SIBO and carbohydrate intolerance, allowing for more appropriate treatment decisions.",[57,28,58],"Food Intolerance Syndromes","Breath Tests",[60,61,62,57,63,64],"Irritable bowel syndrome (IBS)","Functional bloating","Functional Diarrhea","Small intestinal bacterial overgrowth syndrome (SIBO)","Hydrogen Breath Test","RECRUITING","2025-08-20",{"date":68,"type":37},"2025-08-28",{"date":70,"type":37},"2025-08-01",{"date":72,"type":22},"2026-12-31",{"name":74,"class":75},"Klinik Arlesheim","OTHER",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":76},"100571563","phase-1-herbal-evaluation-of-artemisia-annua-for-small-intestinal-bacterial-overgrowth-100571563","NCT06721884","Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth","Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth: A Phase I\u002FII Triple-Masked, Placebo-Controlled Trial","HERBA-SIBO","Inclusion Criteria:\n\n* Adults 18 years of age or older\n* IBS-SSS score \\>175\n* Meets North American Consensus criteria for H2 SIBO\n* Willing to take Artecinua™ or placebo as a dietary supplement for 5 weeks\n* Willing to have two lactulose breath tests and do the prep diet 24 hours before and fast overnight before the test\n* Willing to have three blood drawstests and fast overnight before the draw\n* Able to speak, read, and understand English\n* Able to provide informed consent\n* For individuals of child-bearing potential, willing to use an intrauterine device or two other concurrent forms of birth control to prevent pregnancy while enrolled\n\nExclusion Criteria:\n\n* Use of antibiotic pharmaceuticals or supplements 14 days before baseline breath test\n* Initiation of change in diet, medication, or supplement regime within 30 days\n* Hospitalization within the past 3 months\n* Women who are breastfeeding, pregnant, or planning pregnancy in the next 4 months\n* Allergies to any of the ingredients in the study products.\n* Individuals with chronic kidney or liver disease, cancer, colorectal disease and\u002For other rare disorders that at the discretion of the PI or Clinical \\*Investigator may impact their safety or confound trial results\n* The use of any high-risk medications with narrow therapeutic indices metabolized by CYP450 enzymes: Warfarin (CYP2C9), Tacrolimus\u002FCyclosporine (CYP3A4), Efavirenz (CYP2B6), and Codeine (CYP2D6).\n* Drugs requiring activation for efficacy: Clopidogrel (CYP2C19), Codeine (CYP2D6), and Tamoxifen (CYP2D6) (citations).\n* GFR: \\\u003C30 mL\u002Fmin\u002F1.73m²\n* Hepatitis from any cause.\n* Excessive alcohol use (\\> seven drinks\u002Fweek in women and \\> fourteen in men).\n* Hepatic (ALT, AST, bilirubin) and renal (creatinine, estimated GFR) parameters outside of normal range at screening.",{"count":86,"type":22},32,[88,89],"PHASE1","PHASE2","Small intestinal bacterial overgrowth (SIBO) can cause symptoms like bloating, stomach pain, and changes in bowel movements, significantly affecting quality of life. Many people with irritable bowel syndrome (IBS) also have SIBO, and there is growing recognition of how important it is to address this condition. Artemisia annua has shown potential in managing SIBO based on early reports and studies suggesting it can fight bacteria like \\*E. coli\\* and \\*Klebsiella\\*, which are linked to a type of SIBO that produces hydrogen gas.\n\nThis study aims to test if Artemisia annua is safe and well-tolerated for adults with hydrogen-type SIBO. Over five weeks, participants will take either 5 grams of dried Artemisia annua leaves or a placebo. Researchers will monitor safety through blood tests, vital signs, and adverse events, and they will assess symptom changes using questionnaires and breath tests.\n\nThe trial will include up to 32 participants from the Portland, Oregon area. Participants will be randomly assigned to treatment groups, and neither they, the researchers, nor the test administrators will know who is receiving the herb or the placebo. Results will be analyzed using standard statistical methods.\n\nThis study addresses the lack of research on herbal treatments for SIBO. If successful, the findings could lead to larger studies and help expand treatment options for people with SIBO.",[28],[93,94,95,31,96],"randomized controlled trial","placebo","artemisia annua","small intestinal bacterial overgrowth","2025-05-29",{"date":99,"type":37},"2025-06-04",{"date":101,"type":37},"2025-01-01",{"date":103,"type":22},"2026-01",{"name":105,"class":75},"National University of Natural Medicine",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":113,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":5},"100570655","urine-metabolites-in-the-diagnosis-of-disease-100570655","NCT06710067","Urine Metabolites in the Diagnosis of Disease","Observational Study of Urine Metabolites in the Diagnosis of Disease","Inclusion Criteria:\n\n* Age ≥ 18 years of age at time of enrollment.\n* Able and willing to provide a one-time urine sample and comply with all study procedures for the study.\n* Able to understand the study procedures, able to provide consent to participate in the study, and willing to authorize release of relevant protected health information by consenting to a HIPAA medical release form.\n\nExclusion Criteria:\n\n* Known to be pregnant.\n* A medical condition which, in the opinion of the Investigator and\u002For Sponsor, should preclude enrollment in the study.",true,{"count":115,"type":22},1250,"The goal of this observational study is to validate a non-invasive, urine-based diagnostic technology for the detection and differentiation of various gastrointestinal (GI) diseases.\n\nThis research study intends to enroll participants across a range of demographics and GI disease states including colorectal cancer, small intestinal bacterial overgrowth (SIBO), Crohn\\'s disease, and Celiac disease, collect urine samples and clinical data, and use artificial intelligence and machine learning to build disease-specific models which can identify and differentiate a participants' specific GI disease.\n\nThe main questions it aims to answer are:\n\n1. Does the platform identify a disease signal within each disease cohort, compared to normal controls?\n2. How well does the test perform (e.g. sensitivity and specificity\u002Ffalse-positive rate)?",[118,28,119,120],"Colorectal Cancer","Crohn Disease","Celiac Disease","2024-12-11",{"date":123,"type":37},"2024-12-13",{"date":125,"type":37},"2024-10-01",{"date":127,"type":22},"2026-09",{"name":129,"class":130},"Luventix, Inc.","INDUSTRY"]